Lakshminarayanan Varadhan1, Raoul C Reulen2, Maureen Brown3, Richard N Clayton3. 1. Department of Diabetes and Endocrinology, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, ST4 6QG, UK. laks.varadhan@gmail.com. 2. Department of Public Health and Epidemiology, Centre for Childhood Cancer Survivor Studies, University of Birmingham, Birmingham, UK. 3. Department of Diabetes and Endocrinology, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, ST4 6QG, UK.
Abstract
PURPOSE: Acromegaly has traditionally been associated with significant mortality and cardiovascular morbidity. The aim of this study was to assess the overall mortality and improvement in mortality and morbidity in acromegaly and correlate these with cumulative growth hormone exposure. METHODS: All patients treated for acromegaly at our centre until 2012 were analysed in this retrospective observational study. Baseline demographic details such as age at diagnoses, radiological features and pituitary status were obtained on these 167 patients. Cumulative GH levels (GHy) were calculated as a sum of average of GH readings in consecutive years. Mortality rates and development of new diabetes, hypertension and cardiovascular events (stroke, congestive cardiac failure and ischaemic heart disease) were assessed. RESULTS: The SMR for overall cohort was 1.6. There has been a significant improvement in SMR over the past two decades (SMR until 1992 2.5; SMR since 1992 1.0). Cumulative GH exposure was significantly high in patients who died (35.2 vs 24.1, p < 0.01) and in those with incident metabolic or vascular events during follow up (51.6 vs 24.4, p = 0.0001). The cardiovascular event rate of the 'new' cohort was significantly better than the 'old' cohort (8.0 vs. 29.1 %, p < 0.001). CONCLUSION: There has been significant improvement in mortality and morbidity associated with acromegaly, in the setting of routine care in a specialized endocrine unit. Early and effective treatment to 'control' acromegaly could reduce GH exposure and hence vascular comorbidities.
PURPOSE:Acromegaly has traditionally been associated with significant mortality and cardiovascular morbidity. The aim of this study was to assess the overall mortality and improvement in mortality and morbidity in acromegaly and correlate these with cumulative growth hormone exposure. METHODS: All patients treated for acromegaly at our centre until 2012 were analysed in this retrospective observational study. Baseline demographic details such as age at diagnoses, radiological features and pituitary status were obtained on these 167 patients. Cumulative GH levels (GHy) were calculated as a sum of average of GH readings in consecutive years. Mortality rates and development of new diabetes, hypertension and cardiovascular events (stroke, congestive cardiac failure and ischaemic heart disease) were assessed. RESULTS: The SMR for overall cohort was 1.6. There has been a significant improvement in SMR over the past two decades (SMR until 1992 2.5; SMR since 1992 1.0). Cumulative GH exposure was significantly high in patients who died (35.2 vs 24.1, p < 0.01) and in those with incident metabolic or vascular events during follow up (51.6 vs 24.4, p = 0.0001). The cardiovascular event rate of the 'new' cohort was significantly better than the 'old' cohort (8.0 vs. 29.1 %, p < 0.001). CONCLUSION: There has been significant improvement in mortality and morbidity associated with acromegaly, in the setting of routine care in a specialized endocrine unit. Early and effective treatment to 'control' acromegaly could reduce GH exposure and hence vascular comorbidities.
Authors: B Swearingen; F G Barker; L Katznelson; B M Biller; S Grinspoon; A Klibanski; N Moayeri; P M Black; N T Zervas Journal: J Clin Endocrinol Metab Date: 1998-10 Impact factor: 5.958
Authors: I C M Volschan; L Kasuki; C M S Silva; M L Alcantara; R M Saraiva; S S Xavier; M R Gadelha Journal: Pituitary Date: 2017-06 Impact factor: 4.107
Authors: Carlos K B Ferrari; Eduardo L França; Luciane A Monteiro; Bruno L Santos; Alfredo Pereira-Junior; Adenilda C Honorio-França Journal: Iran J Basic Med Sci Date: 2017-01 Impact factor: 2.699
Authors: A Colao; L F S Grasso; M Di Cera; P Thompson-Leduc; W Y Cheng; H C Cheung; M S Duh; M P Neary; A M Pedroncelli; R Maamari; R Pivonello Journal: J Endocrinol Invest Date: 2019-11-18 Impact factor: 5.467
Authors: Renato Cozzi; Maria R Ambrosio; Roberto Attanasio; Alessandro Bozzao; Laura De Marinis; Ernesto De Menis; Edoardo Guastamacchia; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Pietro Maffei; Maurizio Poggi; Vincenzo Toscano; Michele Zini; Philippe Chanson; Laurence Katznelson Journal: Endocr Metab Immune Disord Drug Targets Date: 2020 Impact factor: 2.895
Authors: Whitney W Woodmansee; Murray B Gordon; Mark E Molitch; Adriana G Ioachimescu; Don W Carver; Beloo Mirakhur; David Cox; Roberto Salvatori Journal: Endocrine Date: 2018-05-16 Impact factor: 3.633
Authors: Annamaria Colao; Marcello D Bronstein; Thierry Brue; Laura De Marinis; Maria Fleseriu; Mirtha Guitelman; Gerald Raverot; Ilan Shimon; Jürgen Fleck; Pritam Gupta; Alberto M Pedroncelli; Mônica R Gadelha Journal: Eur J Endocrinol Date: 2020-06 Impact factor: 6.664
Authors: Betina Biagetti; J R Herance; Roser Ferrer; Anna Aulinas; Martina Palomino-Schätzlein; Jordi Mesa; J P Castaño; Raul M Luque; Rafael Simó Journal: J Clin Med Date: 2019-09-26 Impact factor: 4.241
Authors: M B Antsiferov; V S Pronin; T M Alekseeva; O A Ionova; E Y Martynova; Yu E Poteshkin; N A Chubrova; K Y Zherebchikova Journal: Probl Endokrinol (Mosk) Date: 2021-01-08